Butterfly Biosciences

Butterfly Biosciences is a private, pre-market medical technology company targeting the significant inefficiencies in gynecologic diagnosis and care. Its core innovation is the Butterfly InSights platform, an integrated system that allows non-specialist physicians to perform intrauterine diagnostics and treatments in a single office visit, supported by AI-driven analytics. The company is currently in the development and regulatory phase, with plans to commence commercialization in 2025-2026 and achieve FDA clearance for market entry in 2027, addressing a large market of millions of women presenting with gynecologic conditions annually.

The Butterfly InSights platform is an integrated, in-office system for intrauterine diagnosis and treatment. It combines a miniaturized, articulated device with HD visualization, automated control, and safety features (fluid deficit monitoring, pressure management) to enable non-specialist physicians to perform procedures. The platform is augmented by AI and machine learning for diagnostic analysis and pathology identification.

Butterfly operates in the women's health tech space, competing against traditional surgical device companies (e.g., for hysteroscopes) and possibly other startups aiming to decentralize gynecologic care. Its key differentiator is the full integration of a procedure platform with AI diagnostics designed specifically for use by non-specialists in an office setting.